Tango Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
155
- Stock Symbol
-
TNGX
- Investments
-
1
- Share Price
-
$21.75
- (As of Friday Closing)
Tango Therapeutics General Information
Description
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Contact Information
Website
www.tangotx.comCorporate Office
- 201 Brookline Avenue
- Suite 901
- Boston, MA 02215
- United States
Corporate Office
- 201 Brookline Avenue
- Suite 901
- Boston, MA 02215
- United States
Tango Therapeutics Timeline
Tango Therapeutics Stock Performance
As of 20-Nov-2026, Tango Therapeutics’s stock price is $21.75. Its current market cap is $3.68B with 169M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.75 | $22.71 | $8.30 - $34.39 | $3.68B | 169M | 3.4M | -$1.37 |
Tango Therapeutics Financials Summary
As of 30-Sep-2026, Tango Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,224,831 | 1,075,191 | 76,269 | 689,324 |
| Revenue | 0 | 62,384 | 42,069 | 36,527 |
| EBITDA | (220,982) | (104,920) | (135,484) | (105,829) |
| Net Income | (207,998) | (101,594) | (130,302) | (101,744) |
| Total Assets | 1,033,460 | 398,690 | 316,492 | 402,567 |
| Total Debt | 31,179 | 33,570 | 36,493 | 38,920 |
Tango Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tango Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tango Therapeutics Comparisons
Industry
Financing
Details
Tango Therapeutics Competitors (40)
One of Tango Therapeutics’s 40 competitors is Prelude Therapeutics, a Formerly VC-backed company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Prelude Therapeutics | Formerly VC-backed | Wilmington, DE | ||||
| Repare Therapeutics | Formerly VC-backed | Saint-Laurent, Canada | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY |
Tango Therapeutics Patents
Tango Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026148158-A1 | Compounds and methods of use | Pending | 31-Dec-2024 | ||
| WO-2026148070-A1 | Compounds and methods of use | Pending | 30-Dec-2024 | ||
| WO-2026148072-A1 | Compounds and methods of use | Pending | 30-Dec-2024 | ||
| WO-2026148073-A1 | Compounds and methods of use | Pending | 30-Dec-2024 | ||
| WO-2026128522-A1 | Prmt5 inhibitor for the treatment of cancer | Pending | 09-Dec-2024 | A61K31/4162 |
Tango Therapeutics Signals
Tango Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tango Therapeutics Acquisitions (1)
Tango Therapeutics’s most recent deal was a Merger/Acquisition with BCTG Acquisition. The deal was made on 10-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BCTG Acquisition | 10-Aug-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Tango Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tango Therapeutics FAQs
-
When was Tango Therapeutics founded?
Tango Therapeutics was founded in 2017.
-
Where is Tango Therapeutics headquartered?
Tango Therapeutics is headquartered in Boston, MA.
-
What is the size of Tango Therapeutics?
Tango Therapeutics has 155 total employees.
-
What industry is Tango Therapeutics in?
Tango Therapeutics’s primary industry is Drug Discovery.
-
Is Tango Therapeutics a private or public company?
Tango Therapeutics is a Public company.
-
What is Tango Therapeutics’s stock symbol?
The ticker symbol for Tango Therapeutics is TNGX.
-
What is the current stock price of Tango Therapeutics?
As of 20-Nov-2026 the stock price of Tango Therapeutics is $21.75.
-
What is the current market cap of Tango Therapeutics?
The current market capitalization of Tango Therapeutics is $3.68B.
-
Who are Tango Therapeutics’s competitors?
Prelude Therapeutics, Repare Therapeutics, Ayala Pharmaceuticals, Arcus Biosciences, and Innovimmune Biotherapeutics are some of the 40 competitors of Tango Therapeutics.
-
What is Tango Therapeutics’s annual earnings per share (EPS)?
Tango Therapeutics’s EPS for 12 months was -$1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process